ghk-cu typical dosage mg per day Peptide Dosing Guide: Skin, Hair & Safety (2026) GHK-Cu Peptide Therapy: The Definitive

These wide-ranging benefits make it a great option for wellness and longevity

Why this trial matters: First global Phase III success in a disease with no approved targeted therapy Could change management of systemic symptoms and glandular dysfunction Gene Therapy Phase III in Epidermolysis Bullosa Shows Healing Benefit A Phase III gene therapy trial for epidermolysis bullosa (EB) demonstrated significantly better wound healing, less pain, and reduced itching compared with standard care, and the therapy earned FDA approval in 2025 a major advance for this previously untreatable genetic skin disorder

B 192 ZhangY.LuL.JiaJ.JiaL.GeulaC.PeiJ.et al (2014)

Retatrutide is an investigational compound not approved for any therapeutic use

Its low side-effect profile is also reassuring, making it attractive to those looking for alternative healing options